Analysis RVTY 100% YoY Growth Gross Margin Power result VaR
NYQ Β· Healthcare Β· Diagnostics & Research
$140.19
+11.70 (+9.11%)
RVTY Interactive Price Chart & Trading Signals
RVTY Stock Snapshot β Valuation, Risk & Technical Signals
RVTY Key Fundamentals, Analyst Targets & Company Profile
Key Financial Ratios
Market Cap
$15.64B
P/E Ratio
67.40
Forward P/E
23.79
PEG Ratio
0.73
P/B Ratio
2.16
EPS
$2.08
Dividend Yield
0.22%
52W Range
$81.22 β $140.22
Beta
1.09
Volume
3.7M
ROE
3.2%
Profit Margin
8.2%
Revenue Growth
1.3%
Gross Margin
55.0%
EV/EBITDA
19.02
Analyst Target
$126.12
The trailing price-to-earnings ratio stands at 67.4x. Forward P/E of 23.8x implies earnings expansion expected. Price-to-book is 2.16x. EV/EBITDA sits at 19.02x. Market capitalization is $15.64B. Revenue is growing at 1.3% on a trailing basis. Earnings are expanding at 1.2%. Profit margins are 8.2%. Return on equity is 3.2%. Beta of 1.09 indicates market-average volatility.
Analyst Consensus
Recommendation
Buy
Low Target
$100.00
Mean Target
$126.12
High Target
$165.00
Based on 17 analysts
About RVTY
Revvity, Inc. provides health sciences solutions, technologies, and services. The company offers instruments, reagents, software, subscriptions, detection and imaging technologies, extended warranties, training and services; and instruments, reagents, assay platforms and software products for early detection of common and rare conditions, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. The company also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for oncology, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies under the AutoDELFIA, chemagic, Chitas, CNGnome, DELFIA, DELFIA Xpress, EONIS, EUROArray , EUROIMMUN, EUROLabWorkstation, EUROLINE, EUROPattern, Evolution Evoya, GSP, Haoyuan, IDS Immunodiagnosticsystems, IDS-i10, IDS-i10T, IDS-i20, IDS-iSYS, iLab, iQ, LifeCycle, LimsLink, Migele, NeoBase, NeoLSD, NEXTFLEX, Panthera Puncher, PreNAT II, Prime, RONIA, SimplicityChrom, Specimen Gate, Superflex, Symbio, T-SPOT, Vanadis, ViaCord, VICTOR2, and WholePanel brand names, as well as under the Accell, AlphaLISA, AlphaPlex, AlphaScreen, Alpha SureFire, AssayMate, BIOCHIPs, BioLegend, Bioo Scientific, BioQule, Brilliant Violet, Ce3D, CellCarrier, Cellaca, Celigo, Cellometer, cell::explorer, Cell-Vive, Chalice, ChemDraw, CHOSOURCE, Dharmacon, and DharmaFECT brand names. The company was formerly known as PerkinElmer, Inc. and changed its name to Revvity, Inc. in April 2023. Revvity, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.
RVTY Deep Dive Analysis
Bottom Line
Verdict
OvervaluedBest for
General investorWatch out for
Premium valuationData confidence
HighRevvity, Inc. (RVTY) trades above our multi-model fair value estimate of $53.40 by approximately 61.9%. Trailing P/E: 67.4x. Profitability signals include profit margin of 8.2% and return on equity of 3.2%. Recent growth metrics show revenue growth of 1.3% and earnings growth of 1.2%. Risk profile: beta of 1.09. Consensus: buy.
RVTY Deep Dive Analysis
Valuation
Overvalued
P/E 67.4x
Price is above what fundamentals suggest.
Growth
Stable
Rev 1.3%
Revenue is moving sideways.
Valuation Snapshot
Revvity, Inc. (RVTY) trades above our multi-model fair value estimate of $53.40 by approximately 61.9%. The trailing price-to-earnings ratio stands at 67.4x. Forward P/E of 23.8x suggests earnings compression ahead. Price-to-sales is 5.4x. Price-to-book is 2.2x. EV/EBITDA sits at 19.0x. Market capitalization is $15.64B.
Why it matters: Paying a premium works only if the company keeps growing faster than expected.
Growth & Profitability
Revenue is growing at 1.3% on a trailing basis. Earnings are expanding at 1.2%. Profit margins are 8.2%. Return on equity is 3.2%. Return on assets is 2.4%.
Why it matters: Stable revenue is fine, but watch for margin pressure that could limit profit growth.
Risk Profile
Beta of 1.09 indicates market-average volatility. Net debt position is $2.32B.
Why it matters: Lower risk means steadier returns, but often with less upside in bull markets.
Analyst Context
Analyst consensus target of $126.12 implies 10.0% downside. Target range spans $100.00 to $165.00. 17 analysts cover the stock. Consensus recommendation: buy.
Why it matters: Analyst targets reflect what professionals expect over 12 months. A wide gap between price and target can mean the market disagrees with the consensus.
Data Methodology & Sources
Market Data (Facts)
- Price, volume, market cap: Yahoo Finance (delayed ~5 min)
- P/E, EPS, revenue, debt: Yahoo Finance fundamentals
- Analyst targets: Yahoo Finance consensus (may lag)
- Insider trades: SEC EDGAR Form 4 filings
QuantSoar Model (Derived)
- Fair Value: 7-model consensus (DCF, Graham, P/E, P/S, DDM, EV/EBITDA, Div Yield) β trimmed inverse-variance weighted
- Margin of Safety = (Fair Value β Live Price) / Live Price Γ 100
- Composite Score: 40% Value + 30% Momentum + 30% Risk
- Verdict Gauge: Base 50 + Valuation(Β±25) + Whale(Β±10) + Macro(Β±10) + Technical(Β±10). Analyst consensus shown separately.
Model outputs are estimates based on available data and are not investment advice. Cross-check with primary sources before making investment decisions.
RVTY Overvalued
Revvity, Inc. (RVTY) trades above our multi-model fair value estimate of $53.40 by approximately 61.9%.
Frequently Asked Questions
ValuationIs RVTY stock overvalued right now?
ValuationWhat is RVTY fair value based on current fundamentals?
RiskHow risky is RVTY compared with other stocks?
GrowthIs RVTY still growing?
AnalystWhat do analysts think about RVTY?
DividendDoes RVTY pay a dividend?
CatalystWhat could change the investment case for RVTY?
Related Stocks
About the Author
Phasakorn Traklang (Peach) β Founder
Phasakorn Traklang (Peach) is the founder of QuantSoar, bringing expertise in SEO, web development, and technical analytics to build an AI-powered investment platform accessible to retail investors worldwide.
Connect on LinkedInInvestment Disclaimer: QuantSoar is for informational purposes only. We do not provide personalized investment advice. Always conduct your own research or consult a financial advisor. SEC
Data: Yahoo Finance / SEC EDGAR / Alpha Vantage / Finnhub. AI outputs verified against source data.